The U.S. Food and Drug Administration (FDA) will hear evidence about whether to allow the prescription of Truvada for pre-exposure prophylaxis (PreP). This means HIV negative individuals (i.e. people who do not have HIV) who engage in high risk sexual behaviors such as, unprotected anal sex, would regularly take the medication to reduce their chances of contracting HIV.These hearings come as a result of Truvada's manufacturer, Gilead Science's requested approval of the drug to be used for PreP in December 2011.
I you are interested in reading more about the studies about Truvada, as well as information about the coverage of the hearing, I recommend reading a recent blog by www.hivandhepatitis.com. The include information about the success of different studies across various populations, as well as a link to background material on the hearing and updates about it.
Leave a comment